在儿科家庭终端护理中加载费诺巴比他:一个案例系列
Jo-Anne J Kelly1, Karen Aisling Griffin1,2, Sidharth Vemuri3,4,5,6
1Palliative Care South East, Narre Warren, VIC, Australia.
Palliative medicine
|December 2, 2025
概括
基于体重的费诺巴比他加重剂量改善了三例儿科息护理病例的症状管理. 这种方法与成人指导方针或没有加载剂量不同,可以在家中更好地缓解耐火症状.
科学领域:
- 抚慰性护理是一种缓解性护理.
- 药理学 药理学是指药理学的学科.
- 儿科 儿科 儿科
背景情况:
- 仅有有限的证据表明,对于耐火性症状的儿科息性家庭护理中使用芬诺巴比他.
- 耐药性症状在末期阶段对儿童和家庭造成重大痛苦.
研究的目的:
- 评价用于治疗儿科息性家庭护理中耐火性症状管理的费诺巴比他.
- 在末期儿科病例中比较不同类型的法诺巴比他剂量策略.
主要方法:
- 在家庭临床息治疗中,三名患有耐火症状的儿科患者的案例研究.
- 在服用巴比他之前对药物调整的审查.
- 费诺巴比特的加载剂量比较:成年人指南,没有,和基于体重.
主要成果:
- 基于体重的费诺巴比他加重剂量,然后进行连续输注,增强了症状管理.
- 这种方法比使用成人指南或省略加重剂量更有效.
- 这三个病例都涉及先前的药物调整.
结论:
- 基于体重的费诺巴比他加重剂量似乎有利于在儿科息护理中管理终端耐火症状.
- 需要进一步的研究,以建立基于证据的指导方针,以此种人群使用巴比他.
- 制定指导方针将确保适当的救济,并支持在家中和平死亡.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231
Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244
Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
Drug Dosing: Infants and Children
234
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
234
Sedatives and Hypnotics Drugs: Barbiturates
907
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
907


